haemophilia a: latest news - GoINPHARMA
Thursday, 25 April 2019 - 9:20

Haemophilia a

Pfizer signs $160m cooperation agreement with Sangamo Therapeutics

Pfizer and Sangamo Therapeutics have announced a cooperation aimed at using the “zinc finger therapy” for the treatment of ALS linked to mutations of the C9ORF72 gene. Thanks to the agreement, Sangamo will receive $12m from Pfizer, plus a potential…

FDA approves Roche’s Hemlibra, novel therapy for hemophilia A

Roche has announced that FDA has approved Hemlibra (emicizumab) for routine prophylaxis in adults and children with haemophilia A with factor VIII inhibitors.  Approximately 30% of haemophilia A patients can develop inhibitors against factor VIII replacement therapies. This puts them…

FDA, priority review for Genentech/Roche’s emicizumab in haemophilia A

Genentech, a member of the Roche Group, announced that FDA accepted a sBLA (Biologics License Application) and granted Priority Review for emicizumab as a prophylaxis treatment for adults, adolescents and children with hemophilia A with factor VIII inhibitors. As part…

Biomarin announces new investments in Ireland

US-based biotech company Biomarin keeps investing in Ireland and expects to complete three new laboratories in Cork before Q3 2018 and to hire 50 new employees in the Cork site, which already has a workforce of 365. Biomarin reached record…

FDA approves Shire’s Adynovate

Shire announced that FDA has approved Adynovate, a treatment for hemophilia A, in pediatric patients under 12 years of age. The product has been approved also for use in surgical settings for both adult and pediatric patients. The approval for…